NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (TGTX), announced today that enrollment has completed in the randomized cohort of the Phase 3 ENHANCE trial evaluating a consolidated ...
Detailed price information for Tg Therapeutics (TGTX-Q) from The Globe and Mail including charting and trades.
TG Therapeutics TGTX announced that it has completed enrollment in the phase III study evaluating the subcutaneous formulation of its sole marketed drug, Briumvi (ublituximab-xiiy), for treating ...
--TG Therapeutics, Inc., announced today that enrollment has commenced in a Phase 3 trial evaluating subcutaneous BRIUMVI, the company’ s anti-CD20 monoclonal antibody, in people with relapsing forms ...
Phase 3 trial evaluated two subcutaneous BRIUMVI dosing regimens; administration every 2 months or every 3 months Top-line data expected year-end 2026/ first quarter 2027 NEW YORK, April 15, 2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results